Cargando…
Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: A retrospective observational study
The introduction of biologic agents opened a new era of treatment of juvenile idiopathic arthritis (JIA) over the past decade. From clinical experience, it appears that biological agents are well tolerated overall, and serious adverse events are rare. However, such clinical studies have not been con...
Autores principales: | Choi, Jeong Yun, Chung, Jee Eun, Park, Ji Hyun, Cho, Yoon Sook, Jung, Yong Woo, Choi, Soo An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226161/ https://www.ncbi.nlm.nih.gov/pubmed/30412634 http://dx.doi.org/10.1371/journal.pone.0204573 |
Ejemplares similares
-
Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009) -
Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011) -
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
por: Verazza, Sara, et al.
Publicado: (2016) -
Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011) -
Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)